Predictors of Clostridioides difficile recurrence across a national cohort of veterans in outpatient, acute, and long-term care settings
C
lostridioides difficile is a gram-positive anaerobe that causes infectious diarrhea that can range in disease severity from mild to severe. 1 One of the greatest challenges in treating Clostridioides difficile infection (CDI) effectively is the high recurrence rate. Reported CDI recurrence rates vary substantially from about 5% to as high as 50% due to differing prevalence in risk factors and definitions for recurrence between studies; however, recurrence typically occurs in about 20% of patients. [2] [3] [4] [5] Following the first recurrence, the risk of an additional episode of CDI increases to between 45% and 65%. 6 Recurrent CDI is challenging to treat and causes significant morbidity, mortality, and reductions in quality of life. 7 Identifying those at highest risk for recurrence could allow for targeted initial CDI management and may improve patient outcomes.
Several risk factors for CDI recurrence have been identified in the general population. 1, [8] [9] [10] [11] Previously identified risk factors include advanced age; use of certain medications, such as non-CDI active antibiotics; gastric acid suppressants; and underlying comorbid or immunocompromising conditions. 1, [8] [9] [10] [11] Previous studies have primarily focused on CDI diagnosed and treated in acute care settings. CDI has become increasingly common in community and longterm care settings and patients often receive care from multiple clinical settings. 12, 13 Current estimates suggest that community-associated CDI accounts for over 20% of cases.
14 Over 60% of cases of healthcare-associated CDI cases may have had onset in long-term care facilities. 13 This fragmented care for CDI among various settings poses a particular challenge for the accurate identification of recurrent disease, as the facility that treats the index episode often may not be the same facility that treats the recurrent episode. 15 The Veterans Health Administration is the largest integrated health care system in the United States, with over 140 medical centers and 1,200 outpatient clinics and long-term care facilities. 16 Use of data from the Veterans Affairs (VA) provides a unique opportunity to study predictors of recurrent CDI among patients diagnosed and treated across clinical settings. Moreover, the veteran population is older, has poorer health status, more medical conditions, and higher medical resource use than the general population. 17 The risk for recurrence in veterans may be different than in the general population, highlighting the need for a comprehensive understanding of the predictors of first recurrence among Veterans with an initial CDI episode. Thus, our work sought to identify independent predictors of first recurrence among a national cohort of veterans with CDI.
Methods
Study design. We conducted a matched case-control study among adults (≥18 years) with a first CDI episode treated in Veterans Affairs (VA) facilities nationally from May 1, 2010 to December 30, 2014 . The Institutional Review Board and the Research and Development Committee of the Providence Veterans Affairs Medical Center approved the study.
The first episode of CDI was the first identified during the study period for each patient with no CDI episodes in the year prior to study inclusion. 18 A CDI episode was defined as a positive stool sample for C. difficile toxins, regardless of testing method (the majority of testing throughout the VA facilities is done through polymerase chain reaction), during an inpatient admission or an outpatient encounter and receipt of at least 2 days of standard CDI treatment (oral or IV metronidazole, oral or rectal vancomycin, or fidaxomicin). 1, 19 The use of the nucleic acid amplification test for CDI diagnostic testing among VA facilities increased from 33% in 2010 to 81% in 2015. 20 Similar to previous work, we used a window of at least 2 days of therapy (at least 1 dose of drug on 2 days, regardless of frequency) to represent exposure. 21, 22 A period of two days was used to indicate real-world initiation of treatment; thus, even if the episode represented colonization, it was being treated as an infection.
First recurrence was defined as a subsequent CDI episode (defined as a positive stool sample or diagnosis code 008. 45 for CDI and at least 2 days of subsequent CDI treatment) at least 14 days after the positive stool test date and within 30 days of the end of treatment of the initial CDI occurrence. As above, at least 2 days of therapy was required for exposure. 21, 22 We used an interval of at least 14 days to distinguish a new recurrent episode from the initial CDI episode similar to previous work. 2, 23 We assessed recurrence up to 30 days after treatment cessation as most recurrences occur within 1 to 3 weeks after the end of treatment. 2, 24, 25 Previous work has shown that the risk for recurrence is greatest 10 days after treatment cessation. 2 The definition of recurrence within 28 to 30 days of the end of CDI treatment is commonly used in clinical trials. [25] [26] [27] Recurrence within 30 days has been used in previous VA and non-VA studies. 28, 29 Cases were defined as patients that experienced 30-day first recurrence and controls were defined as those that did not experience 30-day first recurrence.
Controls were matched to cases with a 4:1 ratio, based on the year of CDI episode, facility, and severity. CDI was defined as severe if the closest white blood cell count was > 15 × 10 3 /μL or the closest serum creatinine was >1.5 g/dL within 7 days of the index treatment date, non-severe if white blood cell count was ≤ 15 × 10 3 /μL and serum creatinine ≤1.5 g/dL, or otherwise unknown. 30 Of patients with a white blood cell count (n = 42,298) and serum creatinine (n = 40,261) within 7 days, 96.3% and 96.0% were within 2 days of treatment, respectively.
Potential predictors. We assessed 215 potential independent predictors of recurrence based on clinical relevance and/or previous work. 1, [8] [9] [10] [11] All potential predictors assessed were selected a priori. Potential predictors included socio-demographics (age, gender, race, ethnicity, and marital status), CDI treatment, admitting source, current comorbidities and medical history (diagnosis
KEY POINTS
• A national case-control study among acute, long-term care, and outpatient veterans with a first Clostridioides difficile infection (CDI) episode identified 32 predictors of first recurrence among 974 cases and 3,896 matched controls.
• Treatment with antibiotics, proton-pump inhibitors (PPIs), immunosuppressants, and underlying disease were among the most important risk factors for CDI recurrence identified.
• Figure 1 presents a timeline of when predictors were assessed.
Statistical analysis. All analyses were performed using SAS software (Version 9.2; SAS Institute Inc., Cary, NC). Demographic and clinical characteristics of cases and controls were analyzed using chi-square or Fisher's exact tests for categorical data and Student's t test or the Wilcoxon rank sum test for continuous data, as appropriate. Independent predictors of first recurrence were identified using backward manual stepwise conditional logistic regression models. 33 In univariate analyses, variables were included in the subsequent multivariable model at a p-value of less than 0.10. Variables were then removed from the multivariable model in a stepwise fashion until all remaining variables within the final model demonstrated statistical significance (p-value < 0.05). Absence of collinearity between the variables in the final model was confirmed from tolerance and variance inflation. Tolerance was above 0.1 and variance inflation was below 10 for all variables included in the model (highest variance inflation was 2.07).
Subgroup analyses were conducted to determine whether predictors varied by initial CDI severity (severe and nonsevere) and treatment setting (acute care and outpatient).
Results
We identified 49,064 patients with an initial CDI episode. The mean age of this cohort was 66.2 years (±14.1 S.D.), 93.5% were male (n = 45,887), and 74.4% were white (n = 36,524). Most patients with initial CDI were treated in the outpatient setting (69.6%, n = 34,146), followed by acute care (27.3%, n = 13,396), and longterm care (2.1%, n = 1,019). Of those with Tables 1 and 2 , several significant differences between cases and controls were observed, including differences in CDI treatment. Metronidazole monotherapy was used in 75.6% of cases (64% of which was oral) and 90% of controls (66% of which was oral).
Our final multivariate model was used to calculate adjusted odds ratios (OR) and identified 32 independent predictors of first recurrence of CDI in veterans, which are listed in the online data ( Results of subgroup analyses by CDI severity and treatment setting can be found in the supplemental material. Use of probiotics and fluoroquinolones prior to initial CDI treatment, use of any antibiotic and PPI after CDI treatment, a principal diagnosis of CDI, and white race remained significant predictors of first recurrence in all subgroups assessed.
Discussion
Our study identified important independent predictors of first recurrence among our national cohort of Veterans with initial CDI. Our study includes patients with CDI diagnosed and treated in various healthcare settings, including both acute and long-term care inpatients and outpatients, and focuses on the veteran population. While several studies have assessed predictors of recurrence in patients with CDI, data on recurrence predictors among the veteran population are limited. 3, 11, 28, 32, 34 Antibiotic use is a well-established risk factor for recurrent CDI. 3, 11, 32 Our results confirm that antibiotic use before, during, and after treatment of the initial CDI episode was strongly associated with recurrence. It is thought that antibiotic use during and after CDI treatment alters the recovering colonic microbiota and contributes to an increased risk for CDI recurrence. 35 Three meta-analyses and/or systematic reviews have shown that continued antibiotic use during and/or after CDI treatment are among the most common risk factors for recurrence. 3, 11, 32 We also confirmed that gastric acid suppression was associated with an increased risk of recurrence among Veterans. Gastric acid suppression is thought to increase the risk of infection through allowing increased passage of C. difficile spores beyond the stomach leading to infection. 11, 36 Previous studies have demonstrated an increased risk of CDI recurrence associated with PPI use and, to a lesser extent, histamine 2 receptor antagonists use. 3, 11, 37, 38 We found that patients treated with PPIs after CDI treatment had an increased risk of CDI recurrence. Similar results were observed among another national cohort of 22,615 Veterans, which found prior antibiotic use and PPI use were predictors of 60-day CDI recurrence. 34 Our results confirmed that several antibiotic classes (specifically, fluoroquinolones, third-or fourth-generation cephalosporins, penicillin/amoxicillin/ or ampicillin, amoxicillin or ampicillin/ beta-lactamase inhibitors, first-or second-generation cephalosporins, and glyco-/glycolipo-/lipopeptides) used prior to and during CDI treatment (specifically, first-or second-generation cephalosporins, penicillin/amoxicillin/ ampicillin, third-or fourth-generation cephalosporins, and glyco-/glycolipo-/ lipopeptides) were associated with an increased risk of recurrence as was use of any antibiotic not used for the treatment of CDI (thus all antibiotics but metronidazole, vancomycin oral/rectal, or fidaxomicin) after CDI treatment. In the previously mentioned VA study, the only antibiotic class independently associated with 60-day recurrence was prior third-or fourth-generation cephalosporin use. 34 While we also identified prior third-or fourth-generation cephalosporin use as an independent predictor, the other classes we identified may be related to the differences in exposure periods assessed between the 2 studies (90 days prior versus 30-days prior, during, and after CDI treatment in our study).
Several studies have been conducted to evaluate the comparative risk of CDI Metronidazole monotherapy for Clostridioides difficile infection was compared with all other Clostridioides difficile infection treatments combined. This variable was removed from the multivariable model during the stepwise removal process and as such was not included in the final multivariate model (Table 3) .
AM J HEALTH-SYST PHARM | VOLUME 76 | NUMBER 9 | MAY 1, 2019 associated with different antibiotic classes. [39] [40] [41] These studies have demonstrated the greatest risk with clindamycin, where odds ratios have been as high as 20 compared to no antibiotics. Agents most commonly associated with a moderate CDI risk include fluoroquinolones, carbapenems, cephalosporins, and penicillins. The frequency and duration of use must also be considered when evaluating risk estimates for different antibiotic classes. Despite the highest risk of CDI being associated with clindamycin in other studies, it was not an independent predictor of recurrence in our study, which may have been due to low use in our high-risk older patient population (4% of patients in the 30 days prior to CDI, 2% during CDI treatment, and 1% after CDI treatment). Similarly, carbapenem use was not a significant predictor of CDI recurrence and was used only used in 3%, 7%, and 4% of patients in the 30 days prior, during, and after CDI treatment, respectively. Fluoroquinolones were associated with the greatest risk of CDI recurrence in our study (OR, 3.35; 95% CI, 2.58-4.34); while the risk of CDI recurrence with other antibiotic classes were similar to each other (ORs range ~1.5-2). Fluoroquinolones are among the most commonly used antibiotics, often inappropriately, and are associated with a moderate risk of CDI. 39, 42 In our study, approximately 11% of controls and 35% of cases were exposed to fluoroquinolones in the 30 days before the initial CDI episode. Our results call for additional efforts in discontinuing inappropriate antibiotics, particularly the overuse of fluoroquinolones, in situations where antibiotics are avoidable. It is also important to note that, not all antibiotics may confer an increased risk of recurrent CDI. 19 Among Veterans with spinal cord injury and disorder, tetracycline use was protective against recurrence. 19 In another non-VA study, patients that received doxycycline had a lower risk of CDI. 43 Further, future work should assess which concomitant antibiotics are most appropriate for patients in situations where antibiotics are necessary and unavoidable.
Probiotics, such as Lactobacillus, Bifidobacteria, or Saccharomyces boulardii, are thought to restore the colonic microbiota in the setting of recurrent CDI, however the role of these agents in treatment or prevention of recurrent CDI is unclear. 44 Initial studies suggested that probiotic use may decrease CDI recurrence when used as adjunctive treatment with vancomycin, however later trials did not confirm these findings. [45] [46] [47] We found that probiotic use prior to and after CDI treatment were actually associated with an increased risk for CDI recurrence (prior: OR, 4.62; Variables are n (%) unless otherwise indicated.
586 AM J HEALTH-SYST PHARM | VOLUME 76 | NUMBER 9 | MAY 1, 2019 95% CI, 2.37-8.98, after: OR, 2.30; 95% CI, 1.35-3.91). A possible explanation for this unexpected finding is that patients at an increased risk for recurrence were recognized as such by physicians and were prescribed probiotics. For example, exposure to antibiotics, particularly higher risk agents such as fluoroquinolones, may have prompted physicians to prescribe probiotics potentially driving our findings. We also found that laxative exposure prior to CDI treatment was a strong predictor of CDI recurrence, a relationship that has not been previously evaluated. However, receipt of a laxative has previously been identified as a predictor of development of CDI. 48 Since laxative use distorts the symptoms of CDI and positive stool samples among those exposed to laxatives may represent colonization versus true infection, we hypothesized laxative exposure prior to the initial CDI episode would not be a significant predictor of subsequent disease recurrence. Our somewhat discordant findings may be related to differences in CDI treatment and potential disease severity between cases and controls exposed to laxatives. Metronidazole monotherapy was used in only 60% of cases exposed to laxatives (n = 30) as compared to 90% of controls exposed to laxatives (n = 68). Standard practice and CDI treatment guideline recommendations at the time of our study supported the use of vancomycin over metronidazole for severe CDI episodes since metronidazole use has been associated with poorer outcomes and higher recurrence rates in patients with severe CDI episodes. 1, 49, 50 Thus, differences in CDI treatment patterns among cases and controls exposed to laxatives may suggest that cases were sicker than controls possibly leading to increased recurrence among the cases exposed to laxatives.
Similar to previous findings we found that certain underlying current or previous (in the year prior) comorbid conditions and immunodeficiency were associated with CDI recurrence. 36, 51, 52 We found that current biliary tract disease and history of abdominal pain, enteritis and colitis, esophageal disorder, and nutrition deficiency were all predictors of recurrence. These conditions may be associated with dysfunction of the intestinal microbiota and/or reduced gastric acid secretion, which may contribute to C. difficile colonization, infection, and recurrence. 53 Patients with these conditions may take gastric acid suppressants or laxatives, but upon further investigation these medication exposures did not appear to be driving findings. Impaired immune response to C. difficile toxins has also been shown to contribute to an increased risk of CDI recurrence. 54 Immunosuppressant use after CDI treatment, current malaise and fatigue, and solid organ cancer, history of HIV infection, multiple myeloma, diabetes mellitus, and chronic obstructive pulmonary disorder were all risk factors for CDI. Immunologic impairment associated with these conditions may contribute to the higher risk of recurrence found in these patients. It is expected that some of these conditions, for example abdominal pain and malaise and fatigue, may correspond with CDI diagnosis as they are symptoms of CDI, and therefore were commonly reported in the time periods assessed.
Other notable predictors of recurrence identified were having a primary diagnosis of CDI and demographic factors. In a single center retrospective chart review, primary diagnosis of CDI was one of the most prevalent risk factors for CDI recurrence. 55 In the hospital setting, a primary diagnosis often represents the main reason for hospitalization. Therefore, this finding may be related to CDI severity, as patients with a primary diagnosis of CDI may have severe CDI symptoms that result in an inpatient hospitalization as compared to those with less severe symptoms. 55 For demographic factors, we found that white race was strongly associated with an increased risk of first CDI recurrence (OR, 5.95; 95% CI, 4.66-7.61). In previous studies, associations between race and ethnicity and risk of recurrence have been inconsistent. 44, 56, 57 Upon further analysis our results do not appear to be driven by differences in CDI treatment and are unlikely due to regional differences as we matched at the facility level. Our findings could be due to differences in genetics, healthcare use or treatment patterns, or other factors.
Our study found that the rate of first recurrence within 30 days of the end of treatment was 6.2%. Our recurrence rates are lower than a recently published national VA study, which found that of 7,538 Veterans with a first CDI episode, 1,223 (16.2%) experienced recurrence within 60 days post-treatment. 34 Differences in rates of recurrence are likely due to differing definitions used to define CDI episodes (IC9-code and positive laboratory value versus positive laboratory value and CDI treatment in our study), differing lengths of followup to identify recurrence (60 days versus 30 days post-treatment in our study), and different study periods (2002 to 2014 versus 2010 to 2014 in our study). 34 Our CDI recurrence rates would have been higher had we extended follow-up for recurrence. It has been reported that CDI recurrence occurs at a rate of 7% to 26% at 30 days. 18 A previous national VA study of 30,326 Veterans with first CDI reported rates of 30-day, 60-day, and 90-day recurrence by CDI type. 28 In this study, the majority of patients (60%, n = 18,260) had health care facility onset CDI and those with health care facility onset CDI had the lowest rates of 30-day recurrence (7.2%). Recurrence rates only increased to 9.5% at 60 days and 10.6% at 90 days.
There are a few limitations to this work. We defined incident CDI as the first episode during the study period with no history of CDI in the year prior to that initial CDI episode. Therefore, the incident CDI may not represent the first episode ever for all patients. Our definition of C. difficile was based on laboratory results and did not include assessment of clinical symptoms (diarrhea), and the potential for misclassification of CDI symptomatic episodes versus asymptomatic carriage exists. We did require receipt of at least 2 days of standard CDI treatment. This practice of combining drug and laboratory data has been used previously; however, capturing only clinically relevant disease remains a challenge when using large datasets. 30 Vancomycin, metronidazole, and fidaxomicin given orally were the primary antibiotics given for treatment of CDI during our study period. However, in patients with an ileus who cannot tolerate oral medications, they may be given i.v. metronidazole or vancomycin rectal. 1 In order to avoid excluding the most severely ill patients, we allowed for i.v. metronidazole and vancomycin rectal monotherapy to meet our definition of standard CDI treatment. 1 There is the potential for misclassification of true disease in asymptomatic patients with positive lab tests treated with i.v. metronidazole for another infection. Another limitation was that we are unable to account for possible treatment or healthcare outside the VA system. In particular, we are unable to account for any over-the-counter medication use not filled in VA pharmacies, such as PPI, histamine H 2 -receptor antagonist, and probiotics, and for patients that may have had their initial CDI or recurrence treated outside of the VA system. Severity was selected a priori as a matching factor in the statistical analysis plan for this study as it is a known predictor of poor outcomes. However, our definition of severity is limited as we only had a single serum creatinine level near CDI treatment initiation, and thus could not assess change from baseline as recommended in the 2010 Infectious Diseases Society of America CDI guidelines which were the guidelines used during our study period (2010-2014). 1 Additionally, laboratory values were not available on all patients to assess severity. Only having one value at baseline, may have led to misclassification of patients into the "severe" category. Treatment patterns of cases and controls suggest this may be minimal as 37% of cases and controls were classified as severe, and about 36% of cases and 33% of controls were treated with options recommended by current guidelines for more severe disease (oral vancomycin, i.v. metronidazole, or combination therapy). 1 However, despite only 40% of cases and controls being categorized as "non-severe, " about 66% were treated with metronidazole oral monotherapy, suggesting an underestimation of non-severe disease. 1 We would not expect misclassification of severity to be differential by case control status. Strain type was also unknown for most patients. As previously mentioned, had we extended the follow-up period for CDI recurrence, rates would have been higher. However, a priori we chose to study 30-day recurrence since previous work has demonstrated that CDI recurrence usually occurs within 30 days following the end of CDI treatment, with most cases occurring within 1 to 3 weeks after treatment. 2, 24, 25, 54, 58 Additionally, most clinical trials have assessed outcomes at 28 to 30 days from the end of treatment. A recent systematic review of CDI treatments in 24 randomized controlled trials reporting recurrence rates, found that follow-up time was between 21 and 30 days from end of treatment for all studies except one which reported outcomes at 56 days only. 59 While the length of follow-up used in clinical trials has been consistently within 4 weeks of treatment cessation, that of studies assessing risk factors for CDI recurrence has varied substantially. 3, 59 A systematic review of 33 studies which investigated risk factors for recurrent CDI found that recurrence definitions ranged from less than 21 days to over 180 days from the previous CDI episode. 3 Additionally, accurate identification of recurrent disease from administrative data is challenging. 15 Previous work has shown performance of diagnosis codes, laboratory data, or medication data used alone to accurately identify recurrent disease is poor, and performance only improved moderately when used in combination. 15 Another limitation is that our results on the frequency of metronidazole use are reflective of the practice patterns as recommended by the 2010 Infectious Diseases Society of America guidelines. Since publication of these guidelines, several studies have demonstrated superiority of oral vancomycin over metronidazole. [60] [61] [62] As such current clinical practice and new 2017 guideline recommendations recommend oral vancomycin over metronidazole first line despite disease severity. 61, 63 The high frequency of metronidazole use in our study cohort limited our ability to evaluate other standard CDI treatment options (vancomycin or fidaxomicin) individually. The generalizability of this work to the general population is limited, as the Veteran population consists primarily of older white men. There may be other unknown predictors that were not included in our study, or known predictors that we could not capture from our data source.
Similar to previous findings, treatment with non-CDI active antibiotics, PPIs, and immunosuppressants, as well as underlying comorbid and immunocompromising conditions were among the most important risk factors for recurrence. Knowledge of predictors could help to optimize management of initial CDI and lower risk of recurrence. Specifically, our results highlight an important opportunity for multidisciplinary providers to not just target inappropriate antibiotic use but also to reduce inappropriate use of PPIs, especially in patients with a history of CDI. As with antibiotics, PPIs are a grossly overused class of medications with important consequences, such as the increased risk for first recurrence. 64 Multidisciplinary providers should be aware of the changing clinical practice in CDI treatment and the increasing role vancomycin oral will play in the treatment of initial disease despite severity.
Conclusion
In a large national cohort of outpatient, acute, and long-term care inpatients, treatment with antibiotics, PPIs, immunosuppressants and underlying disease were among the most important risk factors for first CDI recurrence.
